The PARD3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, engineered to disrupt the PARD3 gene. This gene-edited cell pool provides a genetically heterogeneous loss-of-function model, eliminating the need for single-cell cloning while preserving a representative distribution of knockout genotypes. The polyclonal format is well-suited for functional studies where population-level effects of PARD3 ablation are of primary interest, such as investigating cell polarity, signaling, and migration in a B-cell context. The targeted PARD3 disruption is mediated by CRISPR/Cas9, resulting in a versatile tool for probing the molecular role of this scaffold protein in lymphocyte biology.
The Raji cell line is an Epstein-Barr virus (EBV)-immortalized B lymphoblastoid cell line originally established from a Burkitt lymphoma patient. These cells grow as a non-adherent suspension culture and retain features of mature B lymphocytes, including surface immunoglobulin expression and capacity for antigen presentation. Widely used in immunology and oncology research, Raji cells serve as an established model for studying B-cell receptor (BCR) signaling, apoptosis, and lymphomagenesis. Their malignant origin and EBV-driven transformation provide a relevant background for examining how loss of polarity determinants like PARD3 might influence the behavior of B-cell lymphomas.
PARD3 encodes a scaffolding protein that serves as a core component of the Par3/Par6/aPKC polarity complex, which is fundamental to the establishment and maintenance of apical-basal polarity, tight junction assembly, and directional cell migration. PARD3 directly interacts with key polarity regulators including Par6 (PARD6A), atypical protein kinase C (aPKC; PRKCI/PRKCZ), TIAM1, RAC1, and CDC42, forming a signaling hub that integrates cues from upstream activators such as the BCR, PI3K/Akt, GSK-3??, and Aurora A kinase. Downstream, PARD3 coordinates the localization and function of tight junction proteins (ZO-1, JAM-A, occludin) and modulates cadherin-based adhesions, cytoskeletal remodeling via the CDC42/PAK1 axis, and the Hippo pathway through regulation of YAP/TAZ transcriptional co-activators. In B lymphocytes, this polarity network is implicated in asymmetric cell division, migration, and antigen receptor-mediated polarization.
In the Raji B-cell context, disruption of PARD3 ablates a key organizer of the polarity machinery, leading to profound alterations in cell morphology, adhesion, and migration ?C processes critical for lymphocyte homing and immune surveillance. Knockout of PARD3 is expected to disrupt tight junction-like structures that may form during B-cell interactions, impairing the spatial organization of signaling complexes at the cell cortex. Given the importance of BCR-driven PI3K/Akt and CDC42 signaling in B-cell survival and proliferation, loss of PARD3 could uncouple these pathways from spatial cues, potentially affecting lymphomagenesis and drug sensitivity. This model thus offers a physiologically relevant platform to dissect how polarity-dependent signaling intersects with oncogenic processes in Burkitt lymphoma and other B-cell malignancies.
The PARD3 Knockout Raji Polyclonal Cells enable a broad range of functional investigations. Researchers can employ Western blotting and RT-qPCR to confirm PARD3 knockdown, and immunofluorescence staining with antibodies against Par6, aPKC, or ZO-1 to assess polarity disruption. Flow cytometry-based assays allow for profiling of cell surface markers and BCR signaling, while Transwell migration and adhesion assays directly measure changes in cell motility and substrate attachment. Phospho-signaling analysis, YAP/TAZ transcriptional reporter assays, and RNA-seq can elucidate the downstream consequences on Hippo, PI3K/Akt, and CDC42 pathways. These applications support efforts in drug discovery targeting cell polarity in cancer, functional genomics of hematopoietic malignancies, and the study of B-cell migration and lymphoma pathogenesis. Further information on validation and experimental protocols is available upon request; please contact Ascent Research.
